COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD
HC Q study #143
Source   PDF   Share   Tweet
See all 143 studies
Late treatment study
Guisado-Vasco (Peer Reviewed)
Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)
Retrospective 607 patients reporting results for early outpatient HC Q use with mortality odds ratio OR 0.092 [0.022-0.381], p = 0.001 (65 patients), and for hospital use, mortality odds ratio OR 0.737 [0.38-1.41], p = 0.36 (558 patients). Median age 69.
death, ↓20.3%, p=0.36
death, ↓88.0%, p=0.001, outpatient use
(odds ratio converted to relative risk)
Source   PDF   Share   Tweet
See all 143 studies
Please send us corrections, updates, or comments.